Atossa Genetics, Inc.
United States
178 articles about Atossa Genetics, Inc.
-
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
Atossa Genetics Completes Enrollment In Endoxifen Phase I Study And Provides Update On Fulvestrant Microcatheter Phase II Study
7/25/2017
-
Atossa Genetics Announces Warrant Exercises
7/5/2017
-
Atossa Genetics Receives Positive Safety Committee Assessment Of First Cohort Receiving Oral Formulation Of Endoxifen In Phase I Dose Escalation Study
6/27/2017
-
Atossa Genetics Completes Enrollment In Topical Arm Of Endoxifen Phase I Study
5/25/2017
-
Atossa Genetics Announces First Quarter 2017 Financial Results And Provides Company Update
5/16/2017
-
Atossa Genetics Receives Approval From Institutional Review Board For Continuation Of Its Fulvestrant Microcatheter Phase 2 Study
5/10/2017
-
Atossa Genetics Receives Positive Interim Review From Independent Safety Committee In Phase I Endoxifen Dose Escalation Study
4/21/2017
-
Atossa Genetics Enrolls First Cohort Of Eight Subjects In Endoxifen Study
4/4/2017
-
Atossa Genetics Closes Public Offering
4/3/2017
-
Atossa Genetics Prices $4,000,000 Public Offering
3/30/2017
-
Atossa Genetics Opens Enrollment In Study Of Endoxifen
3/24/2017
-
Atossa Genetics Provides Update On Its Phase 2 Study Of Fulvestrant Administered With Its Microcatheter
1/9/2017
-
Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) As Scientific Advisor
12/27/2016
-
Atossa Genetics Announces Third Quarter 2016 Financial Results And Provides Company Update
11/15/2016
-
Atossa Genetics To Present At Upcoming Investor Conferences In September 2016
9/13/2016
-
Atossa Genetics Regains Compliance With NASDAQ Listing Requirement
9/13/2016
-
Atossa Genetics Prices Underwritten Public Offering of 1,150,000 Common Shares
8/31/2016
-
Atossa Genetics Announces Proposed Public Offering Of Common Stock
8/31/2016
-
Atossa Genetics Announces Reverse Stock Split
8/29/2016